文献速递膀胱癌与上尿路尿路上皮癌

根治性膀胱切除术中应用氨甲环酸对出血、静脉血栓栓塞及生存结局的影响

Intraoperative Tranexamic Acid in Radical Cystectomy: Impact on Bleeding, Thromboembolism, and Survival Outcomes.
PubMed 文献 · J Urol · 2024-12-02

该研究基于梅奥诊所根治性膀胱切除术前瞻性登记数据库,纳入1990至2021年间因膀胱癌行根治性膀胱切除术的2862例患者,将468例接受术中氨甲环酸(TXA)者与未接受者按年龄、新辅助化疗、病理分期和术前血红蛋白1:1匹配。结果显示TXA组术中估计失血量更少(中位600 vs 650 cc)、需要围手术期输血比例更低(31% vs 50%,P < .001),两组90天内深静脉血栓和肺栓塞发生率无差异;校正后TXA与总生存(OS)和癌症特异性生存(CSS)无独立关联,而围手术期输血与较差的OS和CSS相关(P < .001)。

要点

  • TXA组术中估计失血量中位600 cc,低于未接受TXA组的650 cc。
  • TXA组围手术期输血比例为31%,低于未接受TXA组的50%(P < .001)。
  • 两组90天内深静脉血栓和肺栓塞发生率无差异;校正后TXA与OS和CSS无独立关联。

核心结论

  • TXA使用与术中估计失血量和围手术期输血需求显著降低相关,且不增加静脉血栓栓塞风险。
  • 单变量分析中观察到TXA使用与OS和CSS改善相关,但多变量分析中TXA本身与OS或CSS改善无独立关联,而围手术期输血与较差OS和CSS相关(P < .001)。
  • 需要进一步研究以探索减少围手术期输血的策略及其对生存结局的影响。

研究设计与样本

  • 查询梅奥诊所根治性膀胱切除术前瞻性登记数据库,识别1990至2021年间因膀胱癌行根治性膀胱切除术的所有患者。
  • 共2862例患者数据完整,其中468例接受TXA(TXA接受者),按年龄、新辅助化疗、病理分期和术前血红蛋白与未接受TXA组(TXA未接受者)进行1:1匹配。
  • 主要结局为围手术期出血风险、输血需求和静脉血栓栓塞风险;次要结局为TXA对OS和CSS的影响。

主要发现

  • TXA接受者术中估计失血量中位600 cc,TXA未接受者中位650 cc。
  • TXA接受者需要围手术期输血的比例为31%,TXA未接受者为50%(P < .001)。
  • 两组在根治性膀胱切除术后90天内深静脉血栓和肺栓塞发生率无差异。
  • 校正生存模型中,TXA使用与OS或CSS无独立显著关联;围手术期输血与较差的OS和CSS相关(P < .001)。
  • 单变量分析中观察到TXA使用与OS和CSS改善相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要进一步研究以探索减少围手术期输血的策略及其对生存结局的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Perioperative blood transfusion (PBT) has been reported in > 50% of patients undergoing radical cystectomy (RC). Unfortunately, PBT in patients undergoing RC has been associated with poor oncological outcomes. Tranexamic acid (TXA) use has been proposed to decrease the need for PBT. Here, we seek to investigate the impact of intraoperative TXA on the risk of perioperative bleeding and venous thromboembolism (VTE) in patients undergoing RC. We also investigate its long-term impact on overall survival (OS) and cancer-specific survival (CSS) outcomes. MATERIALS AND METHODS: We queried the prospectively maintained Mayo Clinic Radical Cystectomy registry and identified all RCs performed for bladder cancer between 1990 and 2021. Primary outcomes assessed include the risk of perioperative bleeding, the need for blood transfusion, and the risk of VTE. Secondary outcomes include the impact of using TXA on OS and CSS. RESULTS: Of 2862 patients with complete available data, 468 received TXA (TXA recipient) and were matched 1:1 for age, neoadjuvant chemotherapy, pathologic staging, and preoperative hemoglobin with a group who did not receive TXA (TXA nonrecipient). TXA recipients experienced less estimated blood loss intraoperatively (median 600 vs 650 cc) and were less likely to need PBT (31% vs 50%, P < .001) compared with TXA nonrecipients. There was no difference between groups in deep venous thrombosis and pulmonary embolism rates within 90 days of RC. In the adjusted survival model, use of TXA was not independently associated with significant impact on OS or CSS. However, perioperative blood transfusion was associated with poor OS and CSS (P < .001). CONCLUSIONS: TXA use was associated with a significant reduction in estimated blood loss and PBT without increased risk of VTE. In univariable analyses, we observed an association between TXA use and improved OS as well as CSS. However, in multivariable analyses, TXA itself was not independently associated with improved OS or CSS; instead, PBT was. Further studies are warranted to explore strategies for minimizing PBTs and their impact on survival outcomes.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Ahmed ME, Andrews JR, Mahmoud AM, et al. Intraoperative Tranexamic Acid in Radical Cystectomy: Impact on Bleeding, Thromboembolism, and Survival Outcomes. J Urol. 2024. PMID: 39621967. doi:10.1097/JU.0000000000004358

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。